Evidence map›Paper›PMID 38348830›Full record

ArticleHIV research & clinical practice2024

Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States.

Karine Dubé, Samuel O Ndukwe, Ana Korolkova, Lynda Dee, Jeremy Sugarman, John A Sauceda

Open access · diamondAbstract read
In one paragraph

Article in HIV research & clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Karine DubéDivision of Infectious Diseases and Global Public Health (IDGPH), Department of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.ORCID 0000-0003-3458-1539
Samuel O NdukweDivision of Infectious Diseases and Global Public Health (IDGPH), Department of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
Ana KorolkovaDivision of Infectious Diseases and Global Public Health (IDGPH), Department of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
Lynda DeeAIDS Action Baltimore, Baltimore, MD, USA.
Jeremy SugarmanJohns Hopkins Berman Institute for Bioethics, Baltimore, MD, USA.ORCID 0000-0001-7022-8332
John A SaucedaDivision of Prevention Science, Center for AIDS Prevention Studies (CAPS), San Francisco, CA, USA.
University of California San Diego · USAIDS United · USJohns Hopkins Berman Institute of Bioethics · USSan Francisco AIDS Foundation · USUniversity of North Carolina at Chapel Hill · US

Funding

Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
Training Program for Scientists Conducting Research to Reduce HIV Health DisparitR25MH067127 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emily A Arnold, Torsten Brian Neilands · 2003 to 2026
$5.4M
Investigating Psychosocial Experiences of HIV Cure Trial Participants Undergoing Extended HIV Treatment Interruptions: Implications for Ethical ConductR01MH126768 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DUBE, KARINE, SAUCEDA, JOHN ANDREW · 2021 to 2025
$3.6M
NIMH NIH HHS P30 MH062246NIMH NIH HHS R01 MH126768NIMH NIH HHS R25 MH067127
6 · The paper itself

Abstract

backgroundThere is limited systematic information available about the perspectives of participants enrolled in intensive combination HIV cure-related trials inclusive of an extended analytical treatment interruption (ATI).

objectiveTo assess and understand experiences of people with HIV involved in a combination HIV cure-related trial with an extended ATI.

methodsThe trial included five interventions and was followed by an ATI lasting up to 52 wk. From 2022 - 2023, we conducted in-depth interviews with study participants following their extended ATIs. Interviews were audio-recorded, transcribed, and analyzed

resultsWe interviewed seven participants. The majority were male, White, and non-Hispanic, with a median age of 37 years. Trust in the research team, scientific altruism and hope of becoming a post-intervention controller were key motivators for joining the trial. Interviewees reported being satisfied with their decision to participate in the trial and the extended ATI. Most recounted feelings of worry related to viral rebound during the ATI. Participants reported both defeat and relief with ART restart. Four faced challenges with protecting partners from HIV during their ATI, such as trying to find out if their partner(s) were using pre-exposure prophylaxis.

conclusionsOur findings demonstrate potential improvements for future ATI trial participant experiences, such as more robust resources for psychosocial support and partner protections. Dedicating greater effort to understanding participant ATI experiences can inform the design of future participant-centered HIV cure trial protocols.

Indexed as

HIV-1HIV InfectionsAdultAnxietyFemaleHumansMaleSan FranciscoTreatment InterruptionUnited Statesanalytical treatment interruptionscombination trialsHIV cure researchparticipant experiencespeople with HIVsocio-behavioral research

Identifiers

PMID38348830
PMCPMC10951555
OpenAlexW4394761170

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.